Insmed Incorporated (0JAV.L)
USD 66.21
(-7.07%)
USD 66.21
(-7.07%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.19 Billion USD | 2.02% |
| 2022 | 1.16 Billion USD | 94.27% |
| 2021 | 602.13 Million USD | 53.49% |
| 2020 | 392.28 Million USD | 1.95% |
| 2019 | 384.77 Million USD | 21.55% |
| 2018 | 316.55 Million USD | 469.69% |
| 2017 | 55.56 Million USD | 1.42% |
| 2016 | 54.79 Million USD | 148.74% |
| 2015 | 22.02 Million USD | -11.38% |
| 2014 | 24.85 Million USD | 52.14% |
| 2013 | 16.33 Million USD | 0.33% |
| 2012 | 16.28 Million USD | 1395.41% |
| 2011 | 1.08 Million USD | 1212.05% |
| 2010 | 83 Thousand USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 487 Thousand USD | -76.95% |
| 2007 | 2.11 Million USD | -33.15% |
| 2006 | 3.16 Million USD | -50.89% |
| 2005 | 6.43 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.1 Billion USD | 4.79% |
| 2024 Q1 | 1.09 Billion USD | -18.72% |
| 2024 Q3 | 989.36 Million USD | 13.29% |
| 2023 FY | 1.19 Billion USD | 2.02% |
| 2023 Q3 | 1.18 Billion USD | 0.61% |
| 2023 Q2 | 1.18 Billion USD | 0.45% |
| 2023 Q1 | 1.17 Billion USD | 0.51% |
| 2023 Q4 | 1.19 Billion USD | 0.43% |
| 2022 Q2 | 825.31 Million USD | -0.15% |
| 2022 Q4 | 1.16 Billion USD | 41.96% |
| 2022 Q1 | 826.54 Million USD | 37.27% |
| 2022 FY | 1.16 Billion USD | 94.27% |
| 2022 Q3 | 823.98 Million USD | -0.16% |
| 2021 Q1 | 400.06 Million USD | 1.98% |
| 2021 Q3 | 594.05 Million USD | 1.33% |
| 2021 Q4 | 602.13 Million USD | 1.36% |
| 2021 Q2 | 586.26 Million USD | 46.55% |
| 2021 FY | 602.13 Million USD | 53.49% |
| 2020 Q4 | 392.28 Million USD | 0.76% |
| 2020 FY | 392.28 Million USD | 1.95% |
| 2020 Q1 | 387.33 Million USD | 0.66% |
| 2020 Q2 | 389.95 Million USD | 0.68% |
| 2020 Q3 | 389.32 Million USD | -0.16% |
| 2019 FY | 384.77 Million USD | 21.55% |
| 2019 Q1 | 357.02 Million USD | 12.78% |
| 2019 Q2 | 359.65 Million USD | 0.74% |
| 2019 Q4 | 384.77 Million USD | 6.17% |
| 2019 Q3 | 362.42 Million USD | 0.77% |
| 2018 Q2 | 307.15 Million USD | 1.47% |
| 2018 FY | 316.55 Million USD | 469.69% |
| 2018 Q4 | 316.55 Million USD | 1.51% |
| 2018 Q1 | 302.7 Million USD | 444.76% |
| 2018 Q3 | 311.86 Million USD | 1.53% |
| 2017 Q4 | 55.56 Million USD | 0.32% |
| 2017 Q3 | 55.38 Million USD | 0.35% |
| 2017 Q2 | 55.19 Million USD | 0.37% |
| 2017 FY | 55.56 Million USD | 1.42% |
| 2017 Q1 | 54.99 Million USD | 0.37% |
| 2016 Q4 | 54.79 Million USD | 57.99% |
| 2016 FY | 54.79 Million USD | 148.74% |
| 2016 Q1 | 19.11 Million USD | -13.22% |
| 2016 Q2 | 16.13 Million USD | -15.58% |
| 2016 Q3 | 34.68 Million USD | 114.93% |
| 2015 Q4 | 22.02 Million USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 22.02 Million USD | -11.38% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | 24.85 Million USD | 68.94% |
| 2014 Q3 | 14.71 Million USD | -10.8% |
| 2014 Q1 | 14.56 Million USD | -10.83% |
| 2014 FY | 24.85 Million USD | 52.14% |
| 2014 Q2 | 16.49 Million USD | 13.21% |
| 2013 FY | 16.33 Million USD | 0.33% |
| 2013 Q1 | 14.55 Million USD | -10.6% |
| 2013 Q2 | 14.92 Million USD | 2.52% |
| 2013 Q4 | 16.33 Million USD | 30.14% |
| 2013 Q3 | 12.55 Million USD | -15.89% |
| 2012 Q3 | 8.58 Million USD | -12.86% |
| 2012 Q2 | 9.85 Million USD | 902.03% |
| 2012 FY | 16.28 Million USD | 1395.41% |
| 2012 Q1 | 983 Thousand USD | -9.73% |
| 2012 Q4 | 16.28 Million USD | 89.74% |
| 2011 Q4 | 1.08 Million USD | 2320.0% |
| 2011 Q3 | 45 Thousand USD | -22.41% |
| 2011 Q2 | 58 Thousand USD | -18.31% |
| 2011 FY | 1.08 Million USD | 1212.05% |
| 2011 Q1 | 71 Thousand USD | -14.46% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | 83 Thousand USD | 0.0% |
| 2010 Q4 | 83 Thousand USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | -100.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 FY | 487 Thousand USD | -76.95% |
| 2008 Q1 | 1.73 Million USD | -17.89% |
| 2008 Q4 | 487 Thousand USD | -40.61% |
| 2008 Q3 | 820 Thousand USD | -39.08% |
| 2008 Q2 | 1.34 Million USD | -22.42% |
| 2007 Q4 | 2.11 Million USD | -6.55% |
| 2007 FY | 2.11 Million USD | -33.15% |
| 2007 Q1 | 3.23 Million USD | 2.31% |
| 2007 Q2 | 2.57 Million USD | -20.41% |
| 2007 Q3 | 2.26 Million USD | -12.16% |
| 2006 Q3 | 3.62 Million USD | 2.17% |
| 2006 Q4 | 3.16 Million USD | -12.78% |
| 2006 Q2 | 3.54 Million USD | 2.1% |
| 2006 Q1 | 3.47 Million USD | -46.03% |
| 2006 FY | 3.16 Million USD | -50.89% |
| 2005 Q2 | 19.81 Million USD | 6.35% |
| 2005 Q3 | 24.17 Million USD | 22.01% |
| 2005 FY | 6.43 Million USD | 0.0% |
| 2005 Q4 | 6.43 Million USD | -73.37% |
| 2005 Q1 | 18.63 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -817.504% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1994.041% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -207.678% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -2511.674% |
| bluebird bio, Inc. | 224.41 Million USD | -431.752% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -3118.404% |
| Imunon, Inc. | 1.13 Million USD | -104644.96% |
| Editas Medicine, Inc. | 24.37 Million USD | -4796.406% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 90.788% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 39.594% |
| Myriad Genetics, Inc. | 130.9 Million USD | -811.652% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -362.002% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -3494.867% |
| Verastem, Inc. | 40.08 Million USD | -2876.979% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 85.165% |
| Waters Corporation | 2.3 Billion USD | 48.239% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 96.188% |
| Biogen Inc. | 7.18 Billion USD | 83.398% |
| Nektar Therapeutics | 112.62 Million USD | -959.58% |
| Perrigo Company plc | 3.63 Billion USD | 67.151% |
| Dynavax Technologies Corporation | 252.41 Million USD | -372.768% |
| Illumina, Inc. | 1.48 Billion USD | 19.855% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -36747.421% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -119235.2% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -586.809% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -4969.68% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -101.208% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -3460.65% |
| Evolus, Inc. | 120.35 Million USD | -891.494% |
| Adicet Bio, Inc. | 17.7 Million USD | -6640.959% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -38720.82% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 55.849% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -137.935% |
| FibroGen, Inc. | 89.69 Million USD | -1230.426% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 56.367% |
| OPKO Health, Inc. | 222.03 Million USD | -437.464% |
| Homology Medicines, Inc. | 43.17 Million USD | -2663.924% |
| Geron Corporation | 35.05 Million USD | -3304.616% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 49.068% |
| Exelixis, Inc. | 189.94 Million USD | -528.265% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -127394.872% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -1133.477% |
| Zoetis Inc. | 6.56 Billion USD | 81.82% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -570.159% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -27009.314% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -64.668% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -3390.354% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 14.783% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -5.372% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 20.403% |
| Blueprint Medicines Corporation | 610.96 Million USD | -95.323% |
| TG Therapeutics, Inc. | 100.11 Million USD | -1091.946% |
| Incyte Corporation | 29.16 Million USD | -3992.147% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -167.268% |